![Page 1: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/1.jpg)
1
BioContact Presentation | Fall 2008www.therapurebio.com
![Page 2: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/2.jpg)
2
13/ of all newproducts
The future of medicine
2
![Page 3: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/3.jpg)
3
$51B
$87B
$25B
$89B
2001
Protein therapeutic market
2005 2010 2010
Worldwide mobile technology market
![Page 4: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/4.jpg)
4
You discovered a protein with blockbuster potential
Specific
Safe
Targeted
Efficacious
Novel
4
![Page 5: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/5.jpg)
5
Ultimately, to get your product approved you will invest…
You are working hard to develop it
5
11 years 5 clinical trials 2,000 patients 39 patents ~$1 billion
![Page 6: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/6.jpg)
66
What about manufacturing?
What about manufacturing?
![Page 7: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/7.jpg)
7
Discovery Development
Marketing Manufacturing 7
![Page 8: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/8.jpg)
8
Scaling up is not easy
Simple
Quick
Inexpensive
Milligrams
commercialbench
Complex
Long lead times - 4-5 years
Expensive -
$150+ million
Kilograms
8
![Page 9: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/9.jpg)
9
Therapure Biopharma:Overcoming the manufacturing barrier
Complex We know protein purification
Long lead times Ready to go now
Quality cGMP compliant
Expensive Established Meadowpine Facility
Regulated We have 8 INDs under our belts
9
![Page 10: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/10.jpg)
10
your trusted partneryour trusted partner
10
for protein manufacturin
g
for protein manufacturin
g
![Page 11: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/11.jpg)
1111
Therapure Biopharma Focus
Provide clients accessto our biomanufacturing capabilities
– Product development– Protein purification – Cell culture– Formulation– Fill– Lyophilization – Finishing
Advance our pipeline• TBI 301
Post-liver transplant & acute and chronic HCV
• TBI 302 Hepatocellular carcinoma & metastatic colorectal cancer
• TBI 303 Proprietary protein modification technology
• TBI 304 Chemotherapy-induced anemia
![Page 12: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/12.jpg)
1212
Experienced Management Team
• Thomas Wellner President and CEO
• Dirk AlkemaVice President, Operations
• Peter Winkley Vice President Finance and Chief Financial Officer
• David Bell Vice President, Drug Development and Chief Scientific Officer
![Page 13: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/13.jpg)
13
About Us
Therapure Biopharma Inc. Canadian-based privately held biopharmaceutical company wholly owned by Catalyst Fund Limited Partnership II and management.
Catalyst Fund Limited Partnership IIA private equity fund with over $1B U.S. in capital that is managed by The Catalyst Capital Group Inc., a Toronto based private equity fund manager.
![Page 14: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/14.jpg)
1414
Ideally located
![Page 15: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/15.jpg)
15
90 minute flight to
60% of the U.S. population15
![Page 16: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/16.jpg)
16
Our Unique and Flexible
Biomanufacturing Facility
16
![Page 17: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/17.jpg)
17
130,000 square feet
5,700 sq.ft. of research laboratories
6,300 sq.ft. of QC labs
30,000 sq.ft. clean room manufacturing
28,000 sq.ft. controlled cGMP warehouse
2,200 sq.ft. GMP clinical pilot suites
![Page 18: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/18.jpg)
18
Large Volume Protein Purification
18
![Page 19: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/19.jpg)
19
Large Scale Processing Capabilities
19
![Page 20: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/20.jpg)
20
Large Volume Storage Capacity
20
![Page 21: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/21.jpg)
21
Central Service Chase
21
![Page 22: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/22.jpg)
22
CIP Units For Process Equipment
22
![Page 23: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/23.jpg)
23
Water For Injection
23
![Page 24: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/24.jpg)
24
Purified Water System
24
![Page 25: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/25.jpg)
25
Clean Rooms and Access Pointsto Meet cGMP Requirements
25
![Page 26: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/26.jpg)
26
QC Laboratories
26
![Page 27: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/27.jpg)
27
Sterile Fill Suite
27
![Page 28: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/28.jpg)
28
Support Beyond Manufacturing
28
![Page 29: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/29.jpg)
29
Biomanufacturing In-licensing Equity partnerships
• Late-stage products
• Approved products in new indications
• Possible targeted investment
Joint development• Innovative financing
• Product co-development
• Process development
• Formulation
• Protein purification
• Fill & finishing
Fee for service
Enhanced partnerships
29
![Page 30: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/30.jpg)
30
Therapure(manufacturing)
Therapure(finance)
$$ (seed capital)
$$ (development fees)
protein product
interest/options
30
Biotech
Equity Partnership
30
![Page 31: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/31.jpg)
31
partnership
Biotech
Therapure Biopharma
Product IP/development
Manufacturing IP/development
31
Joint Development
31
![Page 32: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/32.jpg)
32
Therapure Biopharma Inc.
• Unique and Flexible– Scale of production– Range of production
• Expertise– Scientific– Manufacturing– Regulatory
• Financing opportunities
![Page 33: Therapure Bio Contact Presentation Sept 29 08](https://reader035.vdocument.in/reader035/viewer/2022062418/555f1048d8b42ae8288b5616/html5/thumbnails/33.jpg)
3333
LetLet
bring your biopharmaceutical to the world!
bring your biopharmaceutical to the world!
www.therapurebio.com